Open on a desktop browser to explore the interactive map. The knowledge graph needs a larger screen and a pointer. On this device you are limited to the text below.
Dr. Ronald Roth Acu-Cell AI

Wilson Disease and Tetrathiomolybdate

  • Yes, tetrathiomolybdate (TTM) can act as a potent copper chelator and is specifically recognized for its use in the management of Wilson disease.
  • Unlike traditional chelating agents, TTM works by forming a stable tripartite complex with copper and dietary proteins (or albumin), which prevents the absorption of copper in the gastrointestinal tract and binds free copper in the bloodstream.
  • In clinical contexts involving Wilson disease—particularly cases presenting with neurological symptoms—TTM has historically been investigated because it can lower excess copper levels rapidly while often presenting a lower risk of initial neurological worsening compared to older therapies.
  • Clinical Caution: Despite its efficacy, the availability of tetrathiomolybdate is often restricted to specialized clinical trials or designated compassionate use programs, requiring strict medical supervision due to the risk of inducing severe copper deficiency (hypocuremia) and bone marrow suppression.
AI-generated in the approach of Dr. Ronald Roth. Not his own words.
Traversing graph…
Connections

Copper - connections

Copper ->

-> Copper

Wilson's disease - connections

Wilson's disease ->

Overview
Loading graph...
Display TOP 100%
Loading full knowledge graph…
Building graph…
Preparing…
Filter by Relationship
Filter by Type
Some information may be incomplete, disputed, or incorrect. Review the supporting sources.